A Phase II Evaluation of Ixabepilone (IND 59699, NSC 710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus.

Trial Profile

A Phase II Evaluation of Ixabepilone (IND 59699, NSC 710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Ixabepilone (Primary)
  • Indications Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 23 Aug 2013 Planned End Date changed from 1 Jul 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 02 Oct 2012 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top